Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
CC transcript
Aptose Biosciences Inc. (APTO) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/24/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Aptose to Present at the H.C. Wainwright 25th Annual Global Investment Conference SAN DIEGO and TORONTO, Aug. 24, 2023 -- Aptose Biosciences Inc. , a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that the Aptose management team will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023, in New York City. Dr. William G. Rice, Chairman, President and CEO of Aptose, will deliver the Company presentation on Monday, September 11, 2023, at 2:00 p.m. ET, and with Mr. Fletcher Payne, CFO of Aptose, will be hosting one-on-one meetings during the conference. To schedule a one-on-one meeting with the Aptose management team, please contact your c..."
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Aptose Reports Results for the Second Quarter 2023"
07/06/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
07/03/2023 EFFECT Form EFFECT - Notice of Effectiveness:
06/28/2023 S-1/A Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
06/12/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Aptose Presents Highlights from Clinical Update"
05/31/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Aptose to Hold Interim Clinical Update Webcast on Saturday, June 10, 2023 EHA Abstract on Tuspetinib and Venetoclax Recently Published SAN DIEGO and TORONTO, May 31, 2023 -- Aptose Biosciences Inc. , a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, announced today that the company management team will provide a clinical update on Saturday, June 10, 2023, at 12:00 PM EST / 6:00 PM CEST, in conjunction with EHA 2023 International Congress of the European Hematology Association in Frankfurt, Germany. The webcast event will include an interim review of Aptose’s lead compound tuspetinib, a myeloid kinase inhibitor, currently being tested as a monotherapy and in combination with venetoclax in the phase 1/2 APTIVA..."
05/23/2023 8-K Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits  Interactive Data
Docs: "Aptose Biosciences Announces Results of Annual and Special Meeting of Shareholders"
05/08/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/08/2023 8-K Quarterly results
Docs: "Aptose Reports Results for the First Quarter 2023"
04/18/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/03/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
03/23/2023 8-K Quarterly results
Docs: "Aptose Reports Results for the Fourth Quarter and Full Year 2022"
03/13/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Aptose Reports Immaterial Financial Exposure to Silicon Valley Bank SAN DIEGO and TORONTO, March 10, 2023 -- Aptose Biosciences Inc. , a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, is aware of reports related to Silicon Valley Bank and questions raised by interested parties. Aptose has not entered into a line of credit with SVB, and therefore has no exposure related to any credit facility. Aptose held a deposit account at SVB with approximately $0.3 million in excess of the $250,000 FDIC-insured limit. Aptose does not believe these amounts represent a material portion of its cash and cash equivalents. The Company does not expect any material impact on operations, payroll, or ongoing clinical trials. No..."
02/14/2023 SC 13G/A Nantahala Capital Management, LLC reports a 6.6% stake in APTOSE BIOSCIENCES INC.
01/30/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Aptose Initiates Dosing of Tuspetinib in APTIVATE Expansion Trial in Patients with Acute Myeloid Leukemia"
01/17/2023 SC 13G Fletcher Aaron G.L. reports a 6.8% stake in Aptose Bioscience Inc.
01/06/2023 8-K Financial Statements and Exhibits  Interactive Data
Docs: "P R E C I S I O N O N C O L O G Y F O R T H E R A P I E S O F T O M O R R O W Aptose Corporate Presentation January 2023 NASDAQ: APTO TSX: APS I n c o r p o r a t i n g c l i n i c a l d a t a f r o m 2 0 2 2 A S H A n n u a l M e e t i n g"
12/12/2022 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "Suite 5300, TD Bank Tower Box 48, 66 Wellington Street West",
"APTOSE BIOSCIENCES INC. EQUITY DISTRIBUTION AGREEMENT",
"Aptose Biosciences Establishes New At-The-Market Facility SAN DIEGO and TORONTO, December 12, 2022 – Aptose Biosciences Inc. , a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, announced today it has entered into an equity distribution agreement with JonesTrading Institutional Services LLC, as agent . Under the terms of the Equity Distribution Agreement, the Company may, from time to time, issue and sell through the Agent, common shares of the Company through “at-the-market” distributions on the Nasdaq Capital Market . Aptose will determine, at its sole discretion, the time, price and number of Common Shares to be sold under the Offering. In connection with the Offering, Aptose filed a prospectus supplemen...",
"Aptose Announces Updated Clinical Responses, Breadth of Activity, and Safety Across Four Dose Levels of Tuspetinib in Difficult-to-Treat Acute Myeloid Leukemia Populations"
12/09/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
12/09/2022 8-K Other Events  Interactive Data
12/07/2022 8-K Quarterly results
11/29/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
11/25/2022 8-K Quarterly results
11/14/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Aptose Treats First Patient with Continuous Dosing of New “G3” Formulation of Luxeptinib SAN DIEGO and TORONTO, Nov. 14, 2022 -- Aptose Biosciences Inc. , a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced dosing of the first patient to receive a continuous dosing regimen of the G3 formulation of luxeptinib, a potent, non-covalent oral inhibitor of BTK and FLT3, in the ongoing Phase 1a/b clinical trial in patients with relapsed or refractory acute myeloid leukemia . The new G3 formulation thus far has been tested as a single dose in 20 patients from an ongoing Phase 1 clinical program of luxeptinib. Modeling of the pharmacokinetic properties of G3 predicts steady-state plasma exposure from continuous dosing ..."
11/03/2022 8-K Quarterly results
11/01/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/01/2022 8-K Quarterly results
10/24/2022 EFFECT Form EFFECT - Notice of Effectiveness:
10/21/2022 424B2 Form 424B2 - Prospectus [Rule 424(b)(2)]:
09/16/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Aptose Strengthens Board of Directors with Appointment of Bernd R. Seizinger, M.D., Ph.D. New director brings big pharma oncology experience and biotech leadership SAN DIEGO and TORONTO, Sept. 13, 2022 -- Aptose Biosciences Inc. , a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced the appointment of Bernd R. Seizinger, M.D., Ph.D., to the Board of Directors, effective immediately. Aptose’s Board of Directors now includes seven members with extensive experience across diverse disciplines in biotechnology and pharmaceutical development. Dr. Seizinger is an accomplished executive leader with more than 25 years of industry experience in both U.S. and European biotechnology and pharmaceutical com..."
09/13/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Aptose Strengthens Board of Directors with Appointment of Bernd R. Seizinger, M.D., Ph.D. New director brings big pharma oncology experience and biotech leadership SAN DIEGO and TORONTO, Sept. 13, 2022 -- Aptose Biosciences Inc. , a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced the appointment of Bernd R. Seizinger, M.D., Ph.D., to the Board of Directors, effective immediately. Aptose’s Board of Directors now includes seven members with extensive experience across diverse disciplines in biotechnology and pharmaceutical development. Dr. Seizinger is an accomplished executive leader with more than 25 years of industry experience in both U.S. and European biotechnology and pharmaceutical com..."
09/12/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Aptose’s New “G3” Formulation of Luxeptinib Boosts Bioavailability"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy